Evidence map›Paper›PMID 36337604›Full record

ArticleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2022

Reinfection with SARS-CoV-2 in a patient undergoing chemotherapy for lymphoma: Case report.

Florence Côté, Julie Bestman-Smith, Marie Gourdeau, Shawn M Simpson, Marie-Ève Hamelin, Julie Carbonneau, Antoine Chiasson, Marieke Rozendaal, Martin A Smith, Guy Boivin

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Florence CôtéDépartement de microbiologie et infectiologie, Hôpital de l'Enfant-Jésus, CHU de Québec - Université Laval, Quebec, Quebec, Canada.
Julie Bestman-SmithDépartement de microbiologie et infectiologie, Hôpital de l'Enfant-Jésus, CHU de Québec - Université Laval, Quebec, Quebec, Canada.
Marie GourdeauDépartement de microbiologie et infectiologie, Hôpital de l'Enfant-Jésus, CHU de Québec - Université Laval, Quebec, Quebec, Canada.
Shawn M SimpsonCHU Sainte-Justine Research Centre, Montreal, Quebec, Canada.
Marie-Ève HamelinCHU de Québec - Université Laval and Centre de recherche en infectiologie, Quebec, Quebec, Canada.
Julie CarbonneauCHU de Québec - Université Laval and Centre de recherche en infectiologie, Quebec, Quebec, Canada.
Antoine ChiassonCentre de santé et services sociaux de Chicoutimi, Hôpital de Chicoutimi, Chicoutimi, Quebec, Canada.
Marieke RozendaalCHU Sainte-Justine Research Centre, Montreal, Quebec, Canada.
Martin A SmithCHU Sainte-Justine Research Centre, Montreal, Quebec, Canada.
Guy BoivinCHU de Québec - Université Laval and Centre de recherche en infectiologie, Quebec, Quebec, Canada.ORCID 0000-0003-3027-4662
Centre Hospitalier Universitaire Sainte-Justine · CAHôpital de l'Enfant-Jésus · CAUniversité Laval · CACentre de Santé et de Services Sociaux de Chicoutimi · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 is usually a time-limited disease. However, prolonged infections and reinfections can occur among immunocompromised patients. It can be difficult to distinguish a prolonged infection from a new one, especially when reinfection occurs early.

methodsWe report the case of a 57-year-old man infected with SARS-CoV-2 while undergoing chemotherapy for follicular lymphoma. He experienced prolonged symptomatic infection for 3 months despite a 5-day course of remdesivir and eventually deteriorated and died.

resultsViral genome sequencing showed that his final deterioration was most likely due to reinfection. Serologic studies confirmed that the patient did not seroconvert.

conclusionsThis case report highlights that reinfection can occur rapidly (62-67 d) among immunocompromised patients after a prolonged disease. We provide substantial proof of prolonged infection through repeated nucleic acid amplification tests and positive viral culture at day 56 of the disease course, and we put forward evidence of reinfection with viral genome sequencing.

Indexed as

case reportCOVID-19immunocompromised hostreinfectionSARS-CoV-2viral genome

Identifiers

PMID36337604
PMCPMC9629731
OpenAlexW4288068766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.